

GST reduction and new launches augur well for demand; Buy

CMP (Rs): 1,270 | TP (Rs): 1,475

Retail > Company Update > September 11, 2025

We reiterate BUY on Metro, while revising up our TP by ~14% to Rs1,475 (60x Sep-27E pre-IndAS EPS). The change in TP is led by near-equal contribution from upward revision of estimates and earnings rollover. Given the GST reduction and improving outlook on value-format Walkway, we build in better LTL trends and higher expansion across formats. We also factor in margin gains, helped by operating leverage on Metro's recent tech/team investments and the margin turnaround in FILA (150-250bps impact in FY24/FY25). The recent Metro Crossover (all-day shoes) launch is a perfect match for evolving consumer preferences; new format 'Shoe Depot' should also help cater to the discount-seeking consumer better. Metro's healthy balance sheet (~40% cash) makes it a go-to-partner for incoming global brands, and further portfolio augmentation remains a potential upside.

GST reduction sharpens Walkway positioning; aids overall growth improvement

Metro has \sim 40% sales mix in the <Rs2,500 priced footwear, and GST reduction to 5% should drive higher throughputs, in our view. Assuming demand elasticity of 0.8x and pass-on of the entire benefit to consumers, we see scope of \sim 3% increase in topline and an operating leverage-driven benefit of \sim 7% in EBITDA. In addition, the GST reduction improves prospects for focused value-format Walkway, as it is likely to drive a superior value proposition and accelerate the shift from unorganized channels. Walkway offers the deepest penetration potential, as comparable peer (Bata) has COCO/franchisee penetration in 335/505 unique towns.

Crossover, Shoe Depot - Attractive launches in line with consumer preferences

Metro has recently launched a premium crossover range (priced at Rs4,490-6,990), which combines both fashion and comfort. The products are designed for effortless wear all day long, helped by a Ortholite footbed and a lightweight EVA sole. In addition, Metro has launched own outlet-store format 'Shoe Depot', which addresses the needs of discount-seeking consumers in select markets. The format houses its inhouse brands (*Metro/Mochi*), exclusive brands (*Crocs/Fitflop/FILA*), as well as outside brands (*Puma*).

S&A a big growth lever; Metro making conscious investments

The S&A industry has seen high-teens revenue CAGR over FY19-24 and entails a big growth opportunity, as sports adoption is miniscule in India currently, albeit rising at a rapid pace. Metro has made conscious efforts toward gaining exclusive partnerships (FILA/Footlocker) in setting up dedicated business units (separate P&L) in AI/Analytics technology and in streamlining of its supply chain (BIS challenges). In our view, both Footlocker and FILA have medium-term potential of becoming >Rs10bn brands/formats and are being led by seasoned leaders (Adidas/Nike heritage). Metro's balance sheet is strong and offers further scope for filling white spaces in its S&A portfolio.

| Metro Brands: Finar | cial Snaps | shot (Conso | lidated) | | |
|----------------------------|------------|-------------|----------|--------|-------------|
| Y/E March (Rs mn) | FY24 | FY25 | FY26E | FY27E | FY28E |
| Revenue | 23,567 | 25,074 | 28,129 | 33,224 | 38,987 |
| EBITDA | 6,996 | 7,574 | 8,637 | 10,523 | 12,437 |
| Adj. PAT | 3,814 | 4,280 | 4,991 | 6,133 | 7,176 |
| Adj. EPS (Rs) | 14.0 | 15.7 | 18.3 | 22.5 | 26.4 |
| EBITDA margin (%) | 29.7 | 30.2 | 30.7 | 31.7 | 31.9 |
| EBITDA growth (%) | 3.1 | 8.3 | 14.0 | 21.8 | 18.2 |
| Adj. EPS growth (%) | 1.0 | 11.9 | 16.6 | 22.9 | 17.0 |
| RoE (%) | 22.4 | 24.0 | 26.8 | 27.7 | 27.3 |
| RoIC (%) | 39.3 | 31.8 | 39.2 | 43.5 | 44.3 |
| P/E (x) | 90.4 | 80.8 | 69.3 | 56.4 | 48.2 |
| EV/EBITDA (x) | 48.1 | 44.6 | 38.7 | 31.8 | 26.9 |
| P/B (x) | 18.5 | 20.2 | 17.1 | 14.4 | nite Marque |
| FCFF yield (%) | 1.3 | 1.9 | 1.7 | 1.8 | 2.2 |


Source: Company, Emkay Research

| Target Price – 12M | Sep-26 |
|-----------------------|--------|
| Change in TP (%) | 13.5 |
| Current Reco. | BUY |
| Previous Reco. | BUY |
| Upside/(Downside) (%) | 16.1 |

| Stock Data | METROBRA IN |
|-------------------------|-------------|
| 52-week High (Rs) | 1,331 |
| 52-week Low (Rs) | 890 |
| Shares outstanding (mn) | 272.3 |
| Market-cap (Rs bn) | 346 |
| Market-cap (USD mn) | 3,910 |
| Net-debt, FY26E (Rs mn) | (11,456.8) |
| ADTV-3M (mn shares) | 0 |
| ADTV-3M (Rs mn) | 134.9 |
| ADTV-3M (USD mn) | 1.5 |
| Free float (%) | 15.0 |
| Nifty-50 | 25,005.5 |
| INR/USD | 88.4 |
| Shareholding,Jun-25 | |
| Promoters (%) | 71.9 |
| FPIs/MFs (%) | 3.7/7.4 |

| Price Performance | | | | | | | | |
|-------------------|------|-----|-----|--|--|--|--|--|
| (%) | 1M | 3M | 12M | | | | | |
| Absolute | 13.5 | 1.6 | 2.5 | | | | | |
| Rel. to Nifty | 11.6 | 2.2 | 2.1 | | | | | |

1-Year share price trend (Rs)



Devanshu Bansal

devanshu.bansal@emkayglobal.com +91-22-66121385

Sunny Bhadra

sunny.bhadra@emkayglobal.com +91-22-66121376 Soluut91-31-66121376 whitemarquesolution

> **Yuvraj Kunwar** yuvraj.kunwar@emkayglobal.com +91-22-66121431

Story in charts

Exhibit 1: GST change has been beneficial for footwear players, with the Metro brands portfolio seeing tax benefit of $\sim\!400\text{-}500\text{bps}$

| Metro Brands; | | Pre-GST | | Post-GST | | | |
|----------------------|-----------------|---------|--------------------|-----------------|------------|--------------------|--|
| Price range (Rs) | Revenue mix (%) | | Blended GST (%) | Revenue mix (%) | GST (%) | Blended GST (%) | |
| <1,000 | 7 | 12 | 0.8 | 7 | 5 | 0.4 | |
| 1,000-2,500 | 30 | 18 | 5.4 | 30 | 5 | 1.5 | |
| >2,500 | 63 | 18 | 11.3 | 63 | 18 | 11.3 | |
| Total blended GST | | | 17.6 | | | 13.2 | |


Source: Emkay Research

Exhibit 2: Scenario analysis – Assuming demand elasticity of 0.8x and pass-on of the entire benefit to consumers, we see scope of $\sim\!3\%$ increase in topline and operating leverage driven benefit of $\sim\!7\%$ in EBITDA

| Indexation | Current | Bull- case | Benefit | Remarks |
|------------------------------|---------|---------------|---------|--|
| Gross sales | 117.6 | 117.6 | | Assuming consumer spends remain the same |
| GST (%) | 17.6 | 13.2 | | |
| | | 103.9 | | |
| Demand elasticity factor (x) | | 0.8 | | Assuming demand elasticity of 0.8x |
| Net sales | 100.0 | 103.1 | 3.1% | |
| COGS | 42.3 | 43.6 | | |
| Gross profit | 57.7 | 59.5 | 3.1% | |
| Gross profit margin (%) | 57.7 | 57.7 | | No change in gross margin, assuming the entire benefit is passed on to consumers |
| Fixed opex | 25.0 | 25.0 | | |
| Variable opex | 11.1 | 11.4 | | |
| EBITDA | 21.6 | 23.0 | 6.7% | Operating leverage should drive ~7% EBITDA increase |
| EBITDA margin (%) | 21.6 | 22.4 | | |

Source: Emkay Research

Exhibit 3: Metro has recently launched a premium crossover range (priced at Rs4,490-6,990), which combines both fashion and comfort



Source: Company website, Emkay Research

This report is intended for Team White Marque Solutions(team.emkay@whitemarquesolution

Exhibit 4: New Crossover...



Source: Company website, Emkay Research

Exhibit 5: ...product range



Source: Company website, Emkay Research


Exhibit 6: Metro has launched own outlet-store format 'Shoe Depot', which addresses the needs of the discount-seeking consumer in select markets



Source: Social marketing platforms, Emkay Research


This report is intended for Team White Marque Solutions (team emkay@whitemarquesolution

Exhibit 7: We expect revenue growth to pick up, led by retail space growth and LTL growth across formats




Source: Company, Emkay Research

Exhibit 8: Metro's healthy balance sheet (\sim 40% cash) makes it a go-to-partner for incoming global brands




Source: Company, Emkay Research

Exhibit 9: We build in margin gains, helped by operating leverage on the company's recent tech/team investments and given margin turnaround in FILA (150-250bps impact in FY24/FY25)



Source: Company, Emkay Research; Note: Pre-IndAS EBITDA margin is Emkay estimate

Exhibit 10: We expect the FILA business to see a turnaround by FY27E



Source: Company, Emkay Research


Exhibit 11: Walkway offers the deepest penetration potential as Bata has significantly higher penetration



Source: Company, Emkay Research


his report is intended for Team White Margue Solutions (team emkay@whitemarguesolution

Exhibit 12: In line with global trends, the S&A category has led the overall industry CAGR of ~19% over FY18-24 (vs ~11 overall CAGR for 30 major players in the Indian footwear industry)



Source: Company, MCA (overall, 30 major brands across the footwear category), Emkay Research

Exhibit 13: The S&A category has been led by broad-based growth across most players and entry of new players like Abros, Under Armour, and Birkenstock, over FY18-24



Source: Company, MCA, Emkay Research

Exhibit 14: Change in estimates

| _ | | FY26E | | | FY27E | | | FY28E | |
|--------------------|--------|--------|---------------|--------|--------|---------------|--------|--------|---------------|
| (Rs mn) | Old | New | Change (%) | Old | New | Change (%) | Old | New | Change (%) |
| Revenue | 27,821 | 28,129 | 1.1 | 32,647 | 33,224 | 1.8 | 37,818 | 38,987 | 3.1 |
| EBITDA* | 8,383 | 8,637 | 3.0 | 10,014 | 10,523 | 5.1 | 11,718 | 12,437 | 6.1 |
| EBITDA margin (%)* | 30.1 | 30.7 | 60 bps | 30.7 | 31.7 | 100 bps | 31.0 | 31.9 | 90 bps |
| Adj profit** | 4,675 | 4,991 | 6.8 | 5,673 | 6,133 | 8.1 | 6,601 | 7,176 | 8.7 |
| EPS (Rs) | 17.2 | 18.3 | 6.8 | 20.8 | 22.5 | 8.1 | 24.2 | 26.4 | 8.7 |

Source: Company, Emkay Research; Note: *Post IndAS-116 EBITDA;** Pre IndAS net profit

This report is intended for Team White Margue Solutions (team emkay@whitemarguesolution)

Exhibit 15: Relative valuation comparison of retail companies under Emkay coverage

| Company name | Price | Мсар | Reco | Target Price | I | EPS (Rs) | | | P/E (x) | | EV / | EBITDA | (x)* |
|-----------------------|--------|---------|--------|-----------------|-------|----------|-------|-------|---------|-------|-------|---------------|-------|
| Company name | (Rs) | (Rs bn) | Reco | (Rs) | FY26E | FY27E | FY28E | FY26E | FY27E | FY28E | FY26E | FY27E | FY28E |
| Titan Company | 3,584 | 3,182 | REDUCE | 3,350 | 50.5 | 63.6 | 76.1 | 70.9 | 56.3 | 47.1 | 44.0 | 37.4 | 31.7 |
| Varun Beverages** | 475 | 1,605 | BUY | 575 | 8.9 | 10.7 | 12.9 | 53.4 | 44.4 | 36.7 | 31.4 | 27.2 | 23.7 |
| Ethos | 2,394 | 64 | BUY | 3,500 | 46.8 | 63.5 | 86.3 | 51.2 | 37.7 | 27.8 | 24.1 | 17.5 | 13.2 |
| Aditya Vision | 496 | 64 | BUY | 550 | 9.0 | 12.2 | 15.3 | 55.1 | 40.7 | 32.3 | 28.2 | 21.8 | 17.8 |
| Page Industries | 44,265 | 494 | REDUCE | 39,450 | 741.4 | 834.7 | 933.2 | 59.7 | 53.0 | 47.4 | 40.3 | 35.5 | 31.9 |
| Go Fashion | 734 | 40 | BUY | 900 | 17.2 | 21.3 | 24.6 | 42.7 | 34.5 | 29.8 | 13.0 | 11.1 | 9.9 |
| Jubilant FoodWorks | 652 | 430 | BUY | 825 | 6.3 | 8.4 | 11.0 | 104.2 | 77.4 | 59.1 | 23.7 | 20.3 | 17.4 |
| Devyani International | 189 | 233 | BUY | 190 | 0.0 | 0.6 | 1.4 | NA | 299.7 | 134.1 | 27.8 | 21.0 | 17.1 |
| Westlife Foodworld | 749 | 117 | ADD | 775 | 2.2 | 7.5 | 12.5 | 337.5 | 99.5 | 59.8 | 29.7 | 22.2 | 17.5 |
| Sapphire Foods | 332 | 107 | BUY | 370 | 0.7 | 2.7 | 4.3 | 465.0 | 125.0 | 77.2 | 19.7 | 15.2 | 12.3 |
| Senco Gold | 378 | 62 | BUY | 500 | 14.7 | 19.1 | 25.2 | 25.6 | 19.8 | 15.0 | 13.3 | 10.7 | 8.5 |
| Metro Brands | 1,270 | 346 | BUY | 1,475 | 18.3 | 22.5 | 26.4 | 69.3 | 56.4 | 48.2 | 38.7 | 31.8 | 26.9 |
| ABLBL | 144 | 176 | BUY | 170 | 2.2 | 3.1 | 4.1 | 64.3 | 46.1 | 35.1 | 13.6 | 11.7 | 10.1 |

Source: Company, Emkay Research; Note: *Post IndAS-116 EBITDA; **FY26E is CY25E and so on for Varun Beverages

Fhis report is intended for Team White Marque Solutions(team.emkay@whitemarquesolution

Metro Brands: Consolidated Financials and Valuations

| Profit & Loss | | | | | |
|-----------------------------|--------|--------|--------|--------|--------|
| Y/E March (Rs mn) | FY24 | FY25 | FY26E | FY27E | FY28E |
| Revenue | 23,567 | 25,074 | 28,129 | 33,224 | 38,987 |
| Revenue growth (%) | 10.8 | 6.4 | 12.2 | 18.1 | 17.3 |
| EBITDA | 6,996 | 7,574 | 8,637 | 10,523 | 12,437 |
| EBITDA growth (%) | 3.1 | 8.3 | 14.0 | 21.8 | 18.2 |
| Depreciation & Amortization | 2,291 | 2,580 | 2,911 | 3,395 | 4,028 |
| EBIT | 4,705 | 4,994 | 5,726 | 7,128 | 8,409 |
| EBIT growth (%) | (5.5) | 6.2 | 14.7 | 24.5 | 18.0 |
| Other operating income | - | - | - | - | - |
| Other income | 708 | 930 | 1,100 | 1,250 | 1,400 |
| Financial expense | 789 | 905 | 1,001 | 1,177 | 1,410 |
| PBT | 4,624 | 5,019 | 5,824 | 7,201 | 8,399 |
| Extraordinary items | 0 | 0 | 0 | 0 | 0 |
| Taxes | 499 | 1,491 | 1,456 | 1,800 | 2,100 |
| Minority interest | (30) | (39) | (44) | (51) | (59) |
| Income from JV/Associates | 30 | 16 | 20 | 23 | 27 |
| Reported PAT | 3,814 | 4,280 | 4,991 | 6,133 | 7,176 |
| PAT growth (%) | 14.1 | (15.0) | 23.9 | 23.7 | 16.7 |
| Adjusted PAT | 3,814 | 4,280 | 4,991 | 6,133 | 7,176 |
| Diluted EPS (Rs) | 14.0 | 15.7 | 18.3 | 22.5 | 26.4 |
| Diluted EPS growth (%) | 1.0 | 11.9 | 16.6 | 22.9 | 17.0 |
| DPS (Rs) | 4.3 | 19.9 | 4.7 | 5.8 | 6.7 |
| Dividend payout (%) | 30.3 | 126.6 | 25.4 | 25.6 | 25.5 |
| EBITDA margin (%) | 29.7 | 30.2 | 30.7 | 31.7 | 31.9 |
| EBIT margin (%) | 20.0 | 19.9 | 20.4 | 21.5 | 21.6 |
| Effective tax rate (%) | 10.8 | 29.7 | 25.0 | 25.0 | 25.0 |
| NOPLAT (pre-IndAS) | 4,196 | 3,511 | 4,294 | 5,346 | 6,307 |
| Shares outstanding (mn) | 272 | 272 | 272 | 272 | 272 |

Source: Company, Emkay Research

| Cash flows | | | | | |
|------------------------------|---------|---------|---------|---------|---------|
| Y/E March (Rs mn) | FY24 | FY25 | FY26E | FY27E | FY28E |
| PBT (ex-other income) | 3,916 | 4,090 | 4,724 | 5,951 | 6,999 |
| Others (non-cash items) | 0 | 0 | 0 | 0 | 0 |
| Taxes paid | (499) | (1,491) | (1,456) | (1,800) | (2,100) |
| Change in NWC | (1,167) | 1,139 | (425) | (1,179) | (1,141) |
| Operating cash flow | 5,330 | 7,223 | 6,756 | 7,544 | 9,197 |
| Capital expenditure | (967) | (844) | (1,038) | (1,505) | (1,708) |
| Acquisition of business | 0 | 0 | 0 | 0 | 0 |
| Interest & dividend income | 708 | 930 | 1,100 | 1,250 | 1,400 |
| Investing cash flow | (2,982) | 2,085 | 62 | (255) | (308) |
| Equity raised/(repaid) | 82 | 145 | - | - | - |
| Debt raised/(repaid) | (15) | 0 | 0 | 0 | 0 |
| Payment of lease liabilities | (2,118) | (2,352) | (2,390) | (2,810) | (3,364) |
| Interest paid | (3) | (5) | 0 | 0 | 0 |
| Dividend paid (incl tax) | (1,155) | (5,420) | (1,270) | (1,570) | (1,832) |
| Others | 0 | 0 | 0 | 0 | 0 |
| Financing cash flow | (3,210) | (7,631) | (3,660) | (4,381) | (5,196) |
| Net chg in Cash | (862) | 1,676 | 3,158 | 2,908 | 3,692 |
| OCF | 5,330 | 7,223 | 6,756 | 7,544 | 9,197 |
| Adj. OCF (w/o NWC chg.) | 6,496 | 6,083 | 7,180 | 8,723 | 10,338 |
| FCFF | 4,362 | 6,379 | 5,718 | 6,039 | 7,489 |
| FCFE | 5,068 | 7,304 | 6,818 | 7,289 | 8,889 |
| OCF/EBITDA (%) | 76.2 | 95.4 | 78.2 | 71.7 | 73.9 |
| FCFE/PAT (%) | 132.9 | 170.7 | 136.6 | 118.8 | 123.9 |
| FCFF/NOPLAT (%) | 103.9 | 181.7 | 133.1 | 113.0 | 118.7 |

Source: Company, Emkay Research

| Balance Sheet | | | | | |
|-----------------------------|---------|---------|----------|----------|----------|
| Y/E March (Rs mn) | FY24 | FY25 | FY26E | FY27E | FY28E |
| Share capital | 1,360 | 1,361 | 1,361 | 1,361 | 1,361 |
| Reserves & Surplus | 17,278 | 15,730 | 18,829 | 22,659 | 27,127 |
| Net worth | 18,637 | 17,091 | 20,190 | 24,020 | 28,488 |
| Minority interests | 294 | 289 | 289 | 289 | 289 |
| Non current liab. & prov. | 10,984 | 12,271 | 13,382 | 14,499 | 15,544 |
| Total debt | 0 | 0 | 0 | 0 | 0 |
| Total liabilities & equity | 29,915 | 29,651 | 33,860 | 38,808 | 44,321 |
| Net tangible fixed assets | 5,120 | 5,343 | 5,690 | 6,409 | 7,212 |
| Net intangible assets | - | - | - | - | - |
| Net ROU assets | 9,703 | 10,677 | 10,958 | 11,099 | 10,975 |
| Capital WIP | 93 | 94 | 94 | 94 | 94 |
| Goodwill | 0 | 0 | 0 | 0 | 0 |
| Investments [JV/Associates] | - | - | - | - | - |
| Cash & equivalents | 8,622 | 8,299 | 11,457 | 14,365 | 18,057 |
| Current assets (ex-cash) | 9,989 | 8,932 | 9,807 | 11,554 | 13,513 |
| Current Liab. & Prov. | 3,612 | 3,694 | 4,144 | 4,713 | 5,530 |
| NWC (ex-cash) | 6,377 | 5,238 | 5,662 | 6,842 | 7,983 |
| Total assets | 29,915 | 29,651 | 33,860 | 38,808 | 44,321 |
| Net debt | (8,622) | (8,299) | (11,457) | (14,365) | (18,057) |
| Capital employed | 29,915 | 29,651 | 33,860 | 38,808 | 44,321 |
| Invested capital | 11,497 | 10,581 | 11,352 | 13,251 | 15,194 |
| BVPS (Rs) | 68.6 | 62.8 | 74.2 | 88.2 | 104.6 |
| Net Debt/Equity (x) | (0.5) | (0.5) | (0.6) | (0.6) | (0.6) |
| Net Debt/EBITDA (x) | (1.2) | (1.1) | (1.3) | (1.4) | (1.5) |
| Interest coverage (x) | 5.9 | 5.6 | 5.8 | 6.1 | 6.0 |
| RoCE (%) | 31.2 | 32.6 | 36.1 | 37.4 | 37.0 |

Source: Company, Emkay Research

| Valuations and key Ra | tios | | | | |
|--------------------------|------|------|-------|-------|-------|
| Y/E March | FY24 | FY25 | FY26E | FY27E | FY28E |
| P/E (x) | 90.4 | 80.8 | 69.3 | 56.4 | 48.2 |
| P/CE(x) | 78.5 | 70.6 | 60.8 | 50.0 | 42.8 |
| P/B (x) | 18.5 | 20.2 | 17.1 | 14.4 | 12.1 |
| EV/Sales (x) | 14.3 | 13.5 | 11.9 | 10.1 | 8.6 |
| EV/EBITDA (x) | 48.1 | 44.6 | 38.7 | 31.8 | 26.9 |
| EV/EBIT(x) | 71.5 | 67.6 | 58.4 | 46.9 | 39.8 |
| EV/IC (x) | 29.2 | 31.9 | 29.4 | 25.2 | 22.0 |
| FCFF yield (%) | 1.3 | 1.9 | 1.7 | 1.8 | 2.2 |
| FCFE yield (%) | 1.5 | 2.1 | 2.0 | 2.1 | 2.6 |
| Dividend yield (%) | 0.3 | 1.6 | 0.4 | 0.5 | 0.5 |
| DuPont-RoE split | | | | | |
| Net profit margin (%) | 16.2 | 17.1 | 17.7 | 18.5 | 18.4 |
| Total asset turnover (x) | 1.3 | 1.3 | 1.3 | 1.3 | 1.3 |
| Assets/Equity (x) | 1.1 | 1.1 | 1.1 | 1.1 | 1.2 |
| RoE (%) | 22.4 | 24.0 | 26.8 | 27.7 | 27.3 |
| DuPont-RoIC | | | | | |
| NOPLAT margin (%) | 17.8 | 14.0 | 15.3 | 16.1 | 16.2 |
| IC turnover (x) | 2.2 | 2.3 | 2.6 | 2.7 | 2.7 |
| RoIC (%) | 39.3 | 31.8 | 39.2 | 43.5 | 44.3 |
| Operating metrics | | | | | |
| Core NWC days | 98.8 | 76.2 | 73.5 | 75.2 | 74.7 |
| Total NWC days | 98.8 | 76.2 | 73.5 | 75.2 | 74.7 |
| Fixed asset turnover | 3.5 | 3.3 | 3.4 | 3.5 | 3.5 |
| Opex-to-revenue (%) | 28.4 | 27.5 | 26.8 | 25.6 | 25.2 |

Source: Company, Emkay Research

This report is intended for Team White Margue Solutions (team emkay@whitemarguesolution

RECOMMENDATION HISTORY - DETAILS

| Date | Closing Price (Rs) | TP (Rs) | Rating | Analyst |
|-----------|-----------------------|---------|--------|-----------------|
| 08-Aug-25 | 1,108 | 1,300 | Buy | Devanshu Bansal |
| 24-Jun-25 | 1,141 | 1,400 | Buy | Devanshu Bansal |
| 25-May-25 | 1,211 | 1,400 | Buy | Devanshu Bansal |
| 09-Apr-25 | 1,044 | 1,300 | Buy | Devanshu Bansal |
| 18-Jan-25 | 1,199 | 1,500 | Buy | Devanshu Bansal |
| 10-Jan-25 | 1,259 | 1,500 | Buy | Devanshu Bansal |
| 04-Jan-25 | 1,268 | 1,500 | Buy | Devanshu Bansal |

Source: Company, Emkay Research

RECOMMENDATION HISTORY - TREND



Source: Company, Bloomberg, Emkay Research

Fhis report is intended for Team White Marque Solutions(team.emkay@whitemarquesolution

GENERAL DISCLOSURE/DISCLAIMER BY EMKAY GLOBAL FINANCIAL SERVICES LIMITED (EGFSL):

Emkay Global Financial Services Limited (CIN-L67120MH1995PLC084899) and its affiliates are a full-service, brokerage, investment banking, investment management and financing group. Emkay Global Financial Services Limited (EGFSL) along with its affiliates are participants in virtually all securities trading markets in India. EGFSL was established in 1995 and is one of India's leading brokerage and distribution house. EGFSL is a corporate trading member of BSE Limited (BSE), National Stock Exchange of India Limited (NSE), MCX Stock Exchange Limited (MCX-SX), Multi Commodity Exchange of India Ltd (MCX) and National Commodity & Derivatives Exchange Limited (NCDEX) (hereinafter referred to be as "Stock Exchange(s)"). EGFSL along with its [affiliates] offers the most comprehensive avenues for investments and is engaged in the businesses including stock broking (Institutional and retail), merchant banking, commodity broking, depository participant, portfolio management and services rendered in connection with distribution of primary market issues and financial products like mutual funds, fixed deposits. Details of associates are available on our website i.e. www.emkayglobal.com.

EGFSL is registered as Research Analyst with the Securities and Exchange Board of India ("SEBI") bearing registration Number INH000000354 as per SEBI (Research Analysts) Regulations, 2014. EGFSL hereby declares that it has not defaulted with any Stock Exchange nor its activities were suspended by any Stock Exchange with whom it is registered in last five years. However, SEBI and Stock Exchanges had conducted their routine inspection and based on their observations have issued advice letters or levied minor penalty on EGFSL for certain operational deviations in ordinary/routine course of business. EGFSL has not been debarred from doing business by any Stock Exchange / SEBI or any other authorities; nor has its certificate of registration been cancelled by SEBI at any point of time.

EGFSL offers research services to its existing clients as well as prospects. The analyst for this report certifies that all of the views expressed in this report accurately reflect his or her personal views about the subject company or companies and its or their securities, and no part of his or her compensation was, is or will be, directly or indirectly related to specific recommendations or views expressed in this report.

This report is based on information obtained from public sources and sources believed to be reliable, but no independent verification has been made nor is its accuracy or completeness guaranteed. This report and information herein is solely for informational purpose and shall not be used or considered as an offer document or solicitation of offer to buy or sell or subscribe for securities or other financial instruments. Though disseminated to all the clients simultaneously, not all clients may receive this report at the same time. The securities discussed and opinions expressed in this report may not be suitable for all investors, who must make their own investment decisions, based on their own investment objectives, financial positions and needs of specific recipient.

EGFSL and/or its affiliates may seek investment banking or other business from the company or companies that are the subject of this material. EGFSL may have issued or may issue other reports (on technical or fundamental analysis basis) of the same subject company that are inconsistent with and reach different conclusion from the information, recommendations or information presented in this report or are contrary to those contained in this report. Users of this report may visit www.emkayglobal.com to view all Research Reports of EGFSL. The views and opinions expressed in this document may or may not match or may be contrary with the views, estimates, rating, and target price of the research published by any other analyst or by associate entities of EGFSL; our proprietary trading, investment businesses or other associate entities may make investment decisions that are inconsistent with the recommendations expressed herein. In reviewing these materials, you should be aware that any or all of the foregoing, among other things, may give rise to real or potential conflicts of interest including but not limited to those stated herein. Additionally, other important information regarding our relationships with the company or companies that are the subject of this material is provided herein. All material presented in this report, unless specifically indicated otherwise, is under copyright to Emkay. None of the material, nor its content, nor any copy of it, may be altered in any way, transmitted to, copied or distributed to any other party, without the prior express written permission of EGFSL . All trademarks, service marks and logos used in this report are trademarks or registered trademarks of EGFSL or its affiliates. The information contained herein is not intended for publication or distribution or circulation in any manner whatsoever and any unauthorized reading, dissemination, distribution or copying of this communication is prohibited unless otherwise expressly authorized. Please ensure that you have read "Risk Disclosure Document for Capital Market and Derivatives Segments" as prescribed by Securities and Exchange Board of India before investing in Indian Securities Market. In so far as this report includes current or historic information, it is believed to be reliable, although its accuracy and completeness cannot be guaranteed.

This report has not been reviewed or authorized by any regulatory authority. There is no planned schedule or frequency for updating research report relating to any issuer/subject company.

Please contact the primary analyst for valuation methodologies and assumptions associated with the covered companies or price targets.

Disclaimer for U.S. persons only: Research report is a product of Emkay Global Financial Services Ltd., under Marco Polo Securities 15a6 chaperone service, which is the employer of the research analyst(s) who has prepared the research report. The research analyst(s) preparing the research report is/are resident outside the United States (U.S.) and are not associated persons of any U.S. regulated broker-dealer and therefore the analyst(s) is/are not subject to supervision by a U.S. broker-dealer, and is/are not required to satisfy the regulatory licensing requirements of Financial Institutions Regulatory Authority (FINRA) or required to otherwise comply with U.S. rules or regulations regarding, among other things, communications with a subject company, public appearances and trading securities held by a research analyst account.

This report is intended for distribution to "Major Institutional Investors" as defined by Rule 15a-6(b)(4) of the U.S. Securities and Exchange Act, 1934 (the Exchange Act) and interpretations thereof by U.S. Securities and Exchange Commission (SEC) in reliance on Rule 15a 6(a)(2). If the recipient of this report is not a Major Institutional Investor as specified above, then it should not act upon this report and return the same to the sender. Further, this report may not be copied, duplicated and/or transmitted onward to any U.S. person, which is not the Major Institutional Investor. In reliance on the exemption from registration provided by Rule 15a-6 of the Exchange Act and interpretations thereof by the SEC in order to conduct certain business with Major Institutional Investors. Emkay Global Financial Services Ltd. has entered into a chaperoning agreement with a U.S. registered broker-dealer, Marco Polo Securities Inc. ("Marco Polo"). Transactions in securities discussed in this research report should be effected through Marco Polo or another U.S. registered broker dealer.

This report is intended for Team White Margue Solutions, (team emkay@whitemarguesolution

RESTRICTIONS ON DISTRIBUTION

This report is not directed to, or intended for distribution to or use by, any person or entity who is a citizen or resident of or located in any locality, state, country or other jurisdiction where such distribution, publication, availability or use would be contrary to law or regulation. Except otherwise restricted by laws or regulations, this report is intended only for qualified, professional, institutional or sophisticated investors as defined in the laws and regulations of such jurisdictions. Specifically, this document does not constitute an offer to or solicitation to any U.S. person for the purchase or sale of any financial instrument or as an official confirmation of any transaction to any U.S. person. Unless otherwise stated, this message should not be construed as official confirmation of any transaction. No part of this document may be distributed in Canada or used by private customers in United Kingdom.

ANALYST CERTIFICATION BY EMKAY GLOBAL FINANCIAL SERVICES LIMITED (EGFSL)

The research analyst(s) primarily responsible for the content of this research report, in part or in whole, certifies that the views about the companies and their securities expressed in this report accurately reflect his/her personal views. The analyst(s) also certifies that no part of his/her compensation was, is, or will be, directly or indirectly, related to specific recommendations or views expressed in the report. The research analyst (s) primarily responsible of the content of this research report, in part or in whole, certifies that he or his associated persons1 may have served as an officer, director or employee of the issuer or the new listing applicant (which includes in the case of a real estate investment trust, an officer of the management company of the real estate investment trust; and in the case of any other entity, an officer or its equivalent counterparty of the entity who is responsible for the management of the issuer or the new listing applicant). The research analyst(s) primarily responsible for the content of this research report or his associate may have Financial Interests2 in relation to an issuer or a new listing applicant that the analyst reviews. EGFSL has procedures in place to eliminate, avoid and manage any potential conflicts of interests that may arise in connection with the production of research reports. The research analyst(s) responsible for this report operates as part of a separate and independent team to the investment banking function of the EGFSL and procedures are in place to ensure that confidential information held by either the research or investment banking function is handled appropriately. There is no direct link of EGFSL compensation to any specific investment banking function of the EGFSL.

¹ An associated person is defined as (i) who reports directly or indirectly to such a research analyst in connection with the preparation of the reports; or (ii) another person accustomed or obliged to act in accordance with the directions or instructions of the analyst.

² Financial Interest is defined as interest that are commonly known financial interest, such as investment in the securities in respect of an issuer or a new listing applicant, or financial accommodation arrangement between the issuer or the new listing applicant and the firm or analysis. This term does not include commercial lending conducted at the arm's length, or investments in any collective investment scheme other than an issuer or new listing applicant notwithstanding the fact that the scheme has investments in securities in respect of an issuer or a new listing applicant.

COMPANY-SPECIFIC / REGULATORY DISCLOSURES BY EMKAY GLOBAL FINANCIAL SERVICES LIMITED (EGFSL):

Disclosures by Emkay Global Financial Services Limited (Research Entity) and its Research Analyst under SEBI (Research Analyst) Regulations, 2014 with reference to the subject company(s) covered in this report-:

- 1. EGFSL, its subsidiaries and/or other affiliates and Research Analyst or his/her associate/relative's may have Financial Interest/proprietary positions in the securities recommended in this report as of September 11, 2025
- 2. EGFSL, and/or Research Analyst does not market make in equity securities of the issuer(s) or company(ies) mentioned in this Report

Disclosure of previous investment recommendation produced:

- 3. EGFSL may have published other investment recommendations in respect of the same securities / instruments recommended in this research report during the preceding 12 months. Please contact the primary analyst listed in the first page of this report to view previous investment recommendations published by EGFSL in the preceding 12 months.
- 4. EGFSL, its subsidiaries and/or other affiliates and Research Analyst or his/her relative's may have material conflict of interest in the securities recommended in this report as of September 11, 2025
- 5. EGFSL, its affiliates and Research Analyst or his/her associate/relative's may have actual/beneficial ownership of 1% or more securities of the subject company at the end of the month immediately preceding the September 11, 2025
- 6. EGFSL or its associates may have managed or co-managed public offering of securities for the subject company in the past twelve months.
- 7. EGFSL, its affiliates and Research Analyst or his/her associate may have received compensation in whatever form including compensation for investment banking or merchant banking or brokerage services or for products or services other than investment banking or merchant banking or brokerage services from securities recommended in this report (subject company) in the past 12 months.
- 8. EGFSL, its affiliates and/or and Research Analyst or his/her associate may have received any compensation or other benefits from the subject company or third party in connection with this research report.

Emkay Rating Distribution

| Ratings | Expected Return within the next 12-18 months. | | |
|---------|---|--|--|
| BUY | >15% upside | | |
| ADD | 5-15% upside | | |
| REDUCE | 5% upside to 15% downside | | |
| SELL | >15% downside | | |

Emkay Global Financial Services Ltd.

CIN - L67120MH1995PLC084899

7th Floor, The Ruby, Senapati Bapat Marg, Dadar - West, Mumbai - 400028. India Tel: +91 22 66121212 Fax: +91 22 66121299 Web: www.emkayglobal.com

This report is intended for Team White Margue Solutions (team emkay@whitemarguesolution)

OTHER DISCLAIMERS AND DISCLOSURES:

Other disclosures by Emkay Global Financial Services Limited (Research Entity) and its Research Analyst under SEBI (Research Analyst) Regulations, 2014 with reference to the subject company(s) -:

EGFSL or its associates may have financial interest in the subject company.

Research Analyst or his/her associate/relative's may have financial interest in the subject company.

EGFSL or its associates and Research Analyst or his/her associate/ relative's may have material conflict of interest in the subject company. The research Analyst or research entity (EGFSL) have not been engaged in market making activity for the subject company.

EGFSL or its associates may have actual/beneficial ownership of 1% or more securities of the subject company at the end of the month immediately preceding the date of public appearance or publication of Research Report.

Research Analyst or his/her associate/relatives may have actual/beneficial ownership of 1% or more securities of the subject company at the end of the month immediately preceding the date of public appearance or publication of Research Report.

Research Analyst may have served as an officer, director or employee of the subject company.

EGFSL or its affiliates may have received any compensation including for investment banking or merchant banking or brokerage services from the subject company in the past 12 months. Emkay may have issued or may issue other reports that are inconsistent with and reach different conclusion from the information, recommendations or information presented in this report or are contrary to those contained in this report. Emkay Investors may visit www.emkayglobal.com to view all Research Reports. The views and opinions expressed in this document may or may not match or may be contrary with the views, estimates, rating, and target price of the research published by any other analyst or by associate entities of Emkay; our proprietary trading, investment businesses or other associate entities may make investment decisions that are inconsistent with the recommendations expressed herein. EGFSL or its associates may have received compensation for products or services other than investment banking or merchant banking or brokerage services from the subject company in the past 12 months. EGFSL or its associates may have received any compensation or other benefits from the Subject Company or third party in connection with the research report. EGFSL or its affiliates during twelve months preceding the date of distribution of the research report and EGFSL or its affiliates may have co-managed public offering of securities for the subject company in the past twelve months.

This report is intended for Team White Marque Solutions, (team emkay@whitemarquesolution)